Tenderwize
Retour à la recherche

Open House Original Rebate Contracts 2026-02 - Ponatinib

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 29, 2028 · 612 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-02 - Ponatinib

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value or volume disclosed; potential low revenue.

Contract automatically ends upon patent expiry, shortening the effective period.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclude discount agreements for Ponatinib with all eligible pharmaceutical entrepreneurs.
  • Participants offer Ponatinib at discounted prices to the health insurance funds.
Afficher le résumé complet

This is an Open House procedure for discount agreements (Rabattverträge) for the pharmaceutical product Ponatinib, organized by multiple German health insurance funds led by Techniker Krankenkasse. All eligible pharmaceutical entrepreneurs can join at any time during the contract period (May 2026 – April 2028). No competitive selection; contracts are concluded with all who meet the legal requirements. The estimated contract value is not disclosed, and no exclusivity is granted. The tender is not a public procurement under EU directives; disputes are subject to social court jurisdiction.

Risques

No estimated contract value or volume disclosed; potential low revenue.

Contract automatically ends upon patent expiry, shortening the effective period.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
  • Hold valid marketing authorization for Ponatinib in Germany/EU/EEA.

Eligibility

  • Submit self-declaration of eligibility and reliability (Anlage 4).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Not specified; all eligible participants qualify.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Original Rebate Contracts 2026-02 - Ponatinib

Conclusion of pharmaceutical discount agreements for Ponatinib under §130c SGB V via an Open House procedure with uniform conditions; no individual negotiations; multiple participants allowed.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Not specified; all eligible participants qualify.

Date limite

Deadline Apr 29, 2028

Détails de la procédure

Date de publication
15 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
178647-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3